Pancreatic ductal adenocarcinoma continues to be one of the most lethal cancers today with an abysmal ~8% 5-year survival rate that has remained relatively constant over time. This is thought to be largely due the desmoplastic stroma in the extracellular matrix of these tumor types, inhibiting both the penetration as well as target engagement of treatments. Here we present a methodology for evaluating a monoclonal antibody’s drug target engagement in the presence of an extracellular matrix remodeling drug using paired-agent imaging principles and a subcutaneous tumor mouse model.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.